Medical Pharmacology Chapter 16:  Pharmacology of Antipsychotics Drugs

Section Table of Contents

Site Table of Contents

Previous Page

Next  Page

 
  • Genetic Risk

    • The heritability of schizophrenia is estimated at approximately 65–80%, among the highest of any medical disorder.

      • The concordance rate  in monozygotic twins is approximately 40–50%, and in dizygotic twins 10–15% which confirms a strong genetic influence while demonstrating that predisposition alone is insufficient.4,7 (concordance https://en.wikipedia.org/wiki/Concordance_(genetics))

      • First-degree relatives have a 10-fold increased risk.

      • Genome-Wide Association Study (GWAS) have identified hundreds of common Single Nucleotide Polymorphism (SNPs) of small individual effect. (https://www.genome.gov/genetics-glossary/Genome-Wide-Association-Studies-GWAS); (https://en.wikipedia.org/wiki/Single-nucleotide_polymorphism)

      • The C4A gene, which appears involved in synaptic pruning via the complement cascade during adolescence, as a possible site accounting for some of the genetic risk.3,4

        • Rare copy number variants (CNVs), including deletions at sites 22q11.2 (velocardiofacial syndrome), 1q21.1,and 15q11-13, confer notably elevated individual risk, and findings support the suggestions of shared genetic architecture across schizophrenia, bipolar disorder, autism spectrum disorder, and major depressive disorder.

  • Prenatal and Obstetric Risk Factors

    • The medical literature documents the importance of prenatal and perinatal insults.7

      • Prenatal exposure to maternal influenza infection, particularly during the second trimester,was among the earliest identified risk factors, with the 1957 Helsinki birth cohort providing foundational evidence.

    • Maternal immune activation through Toxoplasma gondii and herpes simplex virus type 2 also conveys risk through immune-mediated disruption of fetal neurodevelopment.

      • Severe maternal nutritional deficiency, as documented in studies of the 1944 Dutch Hunger Winter, doubles the risk of schizophrenia in offspring, implicating nutritional epigenetic mechanisms.7

      • Obstetric complications such as hypoxia, preeclampsia, fetal distress, and low birth weight contribute through hypoxic-ischemic injury to developing dopaminergic and glutamatergic circuits.

        • Advanced paternal age at conception is an independent risk factor, operating through de novo mutations accumulating in the paternal germline.

  • Cannabis and Substance Use

    • Cannabis use is among the most extensively studied and most actionable environmental risk factors for psychosis.8,9,10 

      • Evidence from multiple longitudinal population-based studies  suggests that cannabis use approximately doubles the risk of schizophrenia, with dose-response, frequency-response, and potency-response relationships.

      • Daily users of high-THC-potency cannabis have up to a five-fold increased risk.9 

        • Cannabis also accelerates the age of onset of psychosis by two to five years in vulnerable individuals.

          • Neurobiological mechanism centers on THC action on CB1 receptors in the prefrontal cortex and limbic system, increasing striatal dopamine release.

            • Genetic variation, particularly in the AKT1 and COMT genes, moderates individual susceptibility.9,10 

              • Other substances associated with psychosis include methamphetamine, cocaine, LSD, phencyclidine (PCP), and (in withdrawal) alcohol and benzodiazepines.

  • Psychosocial and Environmental Risk Factors 

    • Urban residence during childhood and adolescence confers a dose-response increase in schizophrenia risk that persists after adjusting for substance use and socioeconomic status.7 

      • The 'social defeat hypothesis' proposes that chronic social exclusion, experienced disproportionately by ethnic minorities, migrants, and individuals in socially fragmented urban environments dysregulates the mesolimbic dopamine system through chronic stress sensitization, lowering the threshold for psychotic decompensation.

      • This assessment the elevated rates of schizophrenia in first- and second-generation migrants and the gradient of urbanicity itself.

    • Childhood adversity, including physical, sexual, and emotional abuse, neglect, bullying, and parental loss seems to be both a strong and dose-dependent risk factor.15 

      • A foundational meta-analysis by Varese et al. (2012), encompassing 36 independent studies, found childhood adversity to be strongly associated with psychosis with a population attributable risk of 33%.15  

      • A subsequent dose-response meta-analysis of 21 studies comprising nearly 60,000 participants found that the odds ratio for psychosis increased from 1.76 (95% CI: 1.39–2.22) for a single exposure to 6.46 (95% CI: 4.37–9.53) for five or more exposures. These data provide evidence for a nonlinear, accelerating dose-response relationship.16

        • Auditory hallucinations in psychosis frequently have content related to past traumatic experiences, and trauma-informed care is important in treating psychotic disorders.17

  • Season of Birth, Immune, and Neurodevelopmental Factors

    • Epidemiological studies have consistently documented a modest but replicable excess of schizophrenia births in late winter and early spring in the Northern Hemisphere, thought to reflect prenatal viral exposure during the second trimester.7

      • The neurodevelopmental hypothesis which is now the dominant etiological paradigm proposes that schizophrenia is fundamentally a disorder of aberrant brain development initiated in utero or during early childhood, manifesting clinically only when the prefrontal cortex reaches full maturation in late adolescence.4,7

        • The apparent late onset is therefore not the beginning of the pathological process but its long-delayed clinical expression, following decades of aberrant synaptic pruning, neuronal connectivity abnormalities, and compensatory mechanisms that ultimately fail under the neurobiological demands of the mature brain.

        • The 'two-hit' model,an early priming insult in a genetically predisposed individual followed by an environmental second hit, remains a useful framework for analyzing etiology.7

Section Table of Contents

Site Table of Contents

Previous Page

Next  Page

 

References
  1. Hany M Rizvi Schizophrenia. StatPearls. S Update: February 23, 2024. National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK539864/

  2. Correll CU, Schooler NR. Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition,
    Assessment, and Treatment. Neuropsychiatr Dis Treat. 2020;16:519–534
    . https://pmc.ncbi.nlm.nih.gov/articles/PMC7041437/

  3. Tandon R, Gaebel W, Barch DM, et al. The schizophrenia syndrome, circa 2024: What we know and how that informs its nature. Schizophr Res. 2024;263:7–18. https://www.sciencedirect.com/science/article/pii/S0920996423004279

  4. Leuch S Siafis S McGrath J McGorry P Howes O Tamminga C Carr R Bighelli I Schneider-Thoma J Priller J Davis J Schizophrenia. Nature Reviews Disease Parameters 11, Article number: 83 (2025). https://www.nature.com/articles/s41572-025-00667-6

  5. Chakrabarti S, Singh N. Psychotic symptoms in bipolar disorder and their impact on the illness: A systematic
    review. World J Psychiatry. 2022;12(8):1204–1232. https://pmc.ncbi.nlm.nih.gov/articles/PMC9521535/

  6. Scott MR, McClung CA. Bipolar Disorder. Curr Opin Neurobiol. 2024;83:102801. https://pmc.ncbi.nlm.nih.gov/articles/PMC10786345/

  7. Misiak B, Stramecki F, Gaweda L, et al. A review of vulnerability and risks for schizophrenia: Beyond the two hit
    hypothesis. Neurosci Biobehav Rev. 2017;84:97–105. https://pmc.ncbi.nlm.nih.gov/articles/PMC4876729/

  8. Hall WD, Degenhardt L. Cannabis use and the risk of developing a psychotic disorder. World Psychiatry.
    2008;7(2):68–71. https://pmc.ncbi.nlm.nih.gov/articles/PMC2424288/

  9. van der Steur SJ, Batalla A, Bossong MG. Factors Moderating the Association between Cannabis Use and
    Psychosis Risk: A Systematic Review. Brain Sci. 2020;10(2):97. https://pmc.ncbi.nlm.nih.gov/articles/PMC7071602

  10. Groening JM, Denton E, Parvaiz R, et al. A systematic evidence map of the association between cannabis use and psychosis-related outcomes. Psychiatry Res. 2024;331:115626. https://pubmed.ncbi.nlm.nih.gov/38096722/

  11. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 1976;261(5562):717–719. https://pubmed.ncbi.nlm.nih.gov/1065924/

  12. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991;148(11):1474–1486. https://pubmed.ncbi.nlm.nih.gov/1681750/

  13. McCutcheon RA, Abi-Dargham A, Howes OD. Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms. Trends Neurosci. 2019;42(3):205–220. https://pmc.ncbi.nlm.nih.gov/articles/PMC6401206/

  14. Howes OD, Murray RM. Schizophrenia: an integrated sociodevelopmental-cognitive model. Lancet. 2014;383(9929):1677–1687. https://pmc.ncbi.nlm.nih.gov/articles/PMC4127444/

  15. Varese F, Smeets F, Drukker M, et al. Childhood adversities increase the risk of psychosis: a meta-analysis of patient-control, prospective- and cross-sectional cohort studies. Schizophr Bull. 2012;38(4):661–671. https://pmc.ncbi.nlm.nih.gov/articles/PMC3406538/

  16. Flinn A, Hefferman-Clarke R, Parker S, et al. Cumulative exposure to childhood adversity and risk of adult psychosis: a dose-response meta-analysis. Psychol Med. 2025;55:e162. https://pubmed.ncbi.nlm.nih.gov/40438025/

  17. Rosenfield PJ, Jiang D, Pauselli L. Childhood adversity and psychotic disorders: Epidemiological evidence, theoretical models and clinical considerations. Schizophr Res. 2021;247:55–66. https://www.sciencedirect.com/science/article/abs/pii/S0920996421002176

  18. Rogers JP, Zandi MS, David AS. The diagnosis and treatment of catatonia. Clin Med (Lond). 2023;23(3):242–245. https://pubmed.ncbi.nlm.nih.gov/37236789/

  19. Rogers JP, Oldham MA, Fricchione G, et al. Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2023;37(4):327–369. https://pubmed.ncbi.nlm.nih.gov/37039129/

  20. Enara AN, Khan SE, Haddad JW, et al. Catatonia: Clinical Overview of the Diagnosis, Treatment, and Clinical Challenges. Medicina (Kaunas). 2021;57(12):1267. https://pmc.ncbi.nlm.nih.gov/articles/PMC8628989/

  21. Connell J, Oldham M, Pandharipande P, et al. Malignant Catatonia: A Review for the Intensivist. J Intensive Care Med. 2023;38(2):137–150. https://pubmed.ncbi.nlm.nih.gov/35861966/

  22. Howes OD, Kambeitz J, Kim E, et al. Defining the Locus of Dopaminergic Dysfunction in Schizophrenia: A Meta-analysis and Test of the Mesolimbic Hypothesis. Schizophr Bull. 2018;44(6):1301–1311. https://pmc.ncbi.nlm.nih.gov/articles/PMC5933516/

  23. Aminoff SR, Onyeka IN, Odegaard M, et al. Lifetime and point prevalence of psychotic symptoms in adults with bipolar disorders: a systematic review and meta-analysis. Psychol Med. 2022;52(13):2413–2425. https://pubmed.ncbi.nlm.nih.gov/36016504/

  24. Fusar-Poli P, Cappucciati M, Rutigliano G, et al. Diagnostic Stability of ICD/DSM First Episode Psychosis Diagnoses: Meta-analysis. Schizophr Bull. 2016;42(6):1395–1406. https://pubmed.ncbi.nlm.nih.gov/27185608/

  25. Elowe J, Conus P, Nguyen A, et al. Psychotic features, particularly mood incongruence, as a hallmark of severity of bipolar I disorder. Front Psychiatry. 2022;13:1003490. https://pmc.ncbi.nlm.nih.gov/articles/PMC9760584/

  26. Arciniegas D Psychosis. Continu um (Minneap Minn). 2015 June;213 Behavior Neurology and Neuropsychiatry): 715-736. https://pmc.ncbi.nlm.nih.gov/articles/PMC4455840/

  27. Psychosis. https://en.wikipedia.org/wiki/Psychosis

  28. Rahman T Lauiello J Schizophrenia: An Overview. Focus (Am Psychiatr Publ). 2016 July 8;14(3): 300-307. https://pmc.ncbi.nlm.nih.gov/articles/PMC6526801/

  29. NHS Website: Symptoms-Psychosis. https://www.nhs.uk/mental-health/conditions/psychosis/symptoms/

  30. Impact of the DSM-IV to DSM-5 Changes on the National Survey on Drug Views and Health. Table 3.22 DSM-IV-DES-5 have schizophrenia Comparison. National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK519704/table/ch3.t22/

  31. Gregory S Understanding the 3 symptom domains of schizophrenia-positive, negative and cognitive symptoms. Article: Schizophrenia. May Clinic Press. https://mcpress.mayoclinic.org/schizophrenia/understanding-the-3-symptom-domains-of-schizophrenia-positive-negative-and-cognitive-symptoms/

  32. Symptoms of Psychosis. epi: never really Psychosis Intervention. https://www.earlypsychosis.ca/symptoms-of-psychosis/

  33. Psychosis. CAMH Mental Health and Addiction Overviews. https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/psychosis

  34. Understanding psychosis. Mental Health Information. National Institute of Mental Health. https://www.nimh.nih.gov/health/publications/understanding-psychosis

DISCLAIMER 

This Web-based pharmacology and disease-based integrated teaching site is based on reference materials, that are believed reliable and consistent with standards accepted at the time of development. Possibility of human error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete. Users should confirm the information contained herein with other sources. This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site. Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals. Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.  Advertisements that appear on this site are not reviewed for content accuracy and it is the responsibility of users of this website to make individual assessments concerning this information.  Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.